Who Shouldn't Do HRT? Medical Exclusions Explained

She had already ordered the pellets online. By the time she sat down across from me, she'd read three books, listened to a dozen podcasts, and decided that hormone replacement therapy was the missing piece. And honestly? For a lot of what she was describing, hot flashes that wrecked her sleep, a libido that had quietly packed its bags, brain fog thick enough to lose her car keys in, she was probably right. But when we got into her history, something came up that made me put the brakes on. Not forever. Just long enough to do this the right way.

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

I run a functional and regenerative medicine practice here in Southlake, and women's hormone therapy is a big part of what we do at Magnolia Functional Wellness. So you might expect me to be the guy who says yes to everyone. I'm not. The truth is that saying "not you" or "not yet" is one of the most important things a hormone physician does. HRT is a genuinely good therapy for the right person. It's also a medication with real biology behind it, and there are situations where the risks tip the scale the wrong way. Knowing the difference is the whole job.

So let's talk about who shouldn't do HRT. Not the fear-based version you've heard secondhand, but the actual medical picture, including the part nobody tells you: a lot of the "reasons" women get turned away aren't real contraindications at all.

Absolute vs. relative: two very different conversations

Before we name names, you need one distinction, because it changes everything. In medicine we split contraindications into two buckets. An absolute contraindication means the door is closed. The condition and the therapy don't mix, and no clever workaround makes it safe. A relative contraindication is different. It means "proceed with caution," or "we need to solve something first," or "this route yes, that route no." Most of what scares women away from hormone therapy lives in that second bucket, not the first.

Why does that matter so much? Because the two get blended together all the time. A woman hears that HRT and blood clots are related, and she assumes that because her mother had a clot, she's disqualified for life. That's not how it works. A good evaluation sorts the true "never" from the "here's how we make it safe," and the gap between those two answers is often the difference between a decade of feeling like yourself and a decade of white-knuckling it. When you read the rest of this, keep asking yourself: is this an absolute, or is it a relative? The answer is rarely as final as people assume.

The cancers that genuinely close the door

Let's start with the one that carries the most weight, because it's real. Active, hormone-receptor-positive breast cancer is a true contraindication to systemic estrogen therapy. Breast tissue that's driven by estrogen doesn't need more estrogen in circulation, full stop. A large 2020 review by Deli and colleagues in Pathologia Oncologica Research did a careful job of sorting tumors by risk, and breast cancer landed squarely in the "disadvantageous and therefore contraindicated" category (Deli et al., 2020). That's not old-fashioned caution. That's the biology telling us something.

The same logic extends to a handful of other estrogen-sensitive cancers, endometrial (uterine) cancer being the classic example, and certain hormone-driven tumors your oncologist would flag. Here's where it gets nuanced, though. Cancer survivorship is not the same as active disease, and the field has grown more thoughtful about that. A 2024 Lancet review on managing menopause after cancer made the point plainly: menopausal hormone therapy is contraindicated or avoided in some situations, but it appears reasonably safe for many other cancer survivors, and blanket refusal can leave women suffering needlessly (Hickey et al., 2024). Interestingly, that same review noted that vaginal estrogen, which acts locally with minimal absorption, seems safe for most women even when systemic therapy is off the table. So even inside the scariest category, the answer isn't always a flat no. It's "which cancer, treated when, and which type of hormone."

What I tell my patients is this: if you've had breast cancer, your oncologist and I need to be in the same conversation. I'm not going to override cancer care to chase a symptom. But I'm also not going to pretend that hot flashes and bone loss don't matter, because they do, and there are non-hormonal tools that help.

Clots, strokes, and the veins nobody thinks about

This is the category where I see the most confusion, and the most unnecessary fear. Estrogen, particularly when you swallow it as a pill, nudges the liver toward making more clotting factors. For most healthy women in their late 40s and 50s, that shift is small and the absolute risk stays low. But for a woman with a history of deep vein thrombosis, pulmonary embolism, a known clotting disorder, or a recent stroke, that same nudge is a bigger deal. Active clotting disease and a history of estrogen-related clots are where I get genuinely careful.

Here's the part that changes the whole conversation, though. The route matters enormously. A 2019 BMJ study by Vinogradova and colleagues looked at more than 80,000 women and found that oral hormone therapy was associated with a meaningfully higher risk of venous clots, while transdermal estrogen, the patches, gels, and creams that bypass the liver's first pass, was not associated with increased clot risk at all (Vinogradova et al., 2019). Read that again. The delivery method flipped the risk. That's why, in my practice, a clotting history usually isn't a hard no. It's a "we're going transdermal, and we're checking a few things first." A relative contraindication, not an absolute one.

The exceptions I won't talk myself out of: a woman with an active clot, an uncontrolled clotting disorder, or a recent cardiovascular event needs to be stable and cleared before hormones enter the picture. Uncontrolled high blood pressure sits in a similar spot. Not a permanent ban, but a "let's fix this first" flag. As the 2021 Annals of Internal Medicine review on menopause put it, the whole point is matching the right patient to the right therapy through honest risk-and-benefit counseling rather than one-size-fits-all rules (McNeil & Merriam, 2021).

Bleeding you can't explain, and a few other red flags

Some contraindications aren't about cancer or clots at all. They're about the fact that hormones can mask a problem you need to see clearly first.

Undiagnosed vaginal bleeding is the big one. If a woman is having abnormal or postmenopausal bleeding and we don't yet know why, starting estrogen is like painting over a water stain without checking the pipe. It can hide, or complicate, a diagnosis that deserves a workup. So the rule is simple: we find out what's causing the bleeding before we start therapy, not after. Almost always the answer is benign, and once it's sorted, the door reopens.

Active liver disease is another. Since oral estrogen is processed heavily by the liver, significant liver dysfunction is a real caution, and again, this is a place where the transdermal route and a careful look at liver function change the math. Pregnancy, or even the possibility of it in a perimenopausal woman who assumes she's "too old" to conceive, is a contraindication for obvious reasons. And a known allergy or severe prior reaction to a specific hormone preparation means we pick a different one, not that we give up.

Notice the pattern. Most of these are conditions that demand we pause, investigate, and choose the right tool. Very few of them are lifetime disqualifications.

The "I was told no" list, and why it's often wrong

Now for the part I care about most, because it's where women get shortchanged. Over the years, plenty of patients have walked into my Southlake office convinced they could never do hormone therapy, and when I ask why, the reason turns out to be something that isn't a contraindication at all.

• "My mom had breast cancer." A family history raises questions worth taking seriously, and it shapes how we screen and monitor. It is not, by itself, an absolute contraindication. Your history is not her diagnosis.
• "I have fibroids" or "I had a hysterectomy." Neither one closes the door. In fact, a woman without a uterus often has a simpler regimen because she may not need progesterone at all.
• "I'm over 60, so it's too late." Age changes the risk-benefit conversation and sometimes the starting dose or route, but a number on a birthday cake is not a diagnosis. Timing and individual health matter more than the calendar.
• "I had one bad experience on the pill in my 20s." Birth control estrogen and menopausal hormone therapy are not the same doses or, often, the same molecules. One doesn't dictate the other.

None of that means everyone's a candidate. It means the reason for a no should be a real one. If you've been turned away, it's fair to ask which bucket your situation actually falls in, absolute or relative, and why. A thorough evaluation, the kind we walk through on our women's hormone replacement therapy visits, is designed to answer exactly that.

How we actually decide at Magnolia

So what does a responsible yes or no look like in practice? It starts with a real history, not a checkbox form. I want to know about clots, cancers, bleeding, liver health, cardiovascular events, blood pressure, and what medications you're already on. Then labs, because you can't manage what you haven't measured, and a genuine look at your symptoms and goals. If something needs clearing first, we clear it. If a coordinating physician needs to weigh in, we loop them in. If the safest route is a patch instead of a pill, that's what we choose.

Sometimes the honest answer is "not right now," and I'll say it even when it's not what a patient hoped to hear. Sometimes it's "not with systemic hormones, but here's what we can safely do instead." And very often, for the woman who was sure she'd be turned away, it's a yes she didn't expect. If you want to understand your own numbers before that conversation, our guide to women's hormone labs is a good place to start.

Here's the takeaway I'd leave you with. Hormone therapy isn't a light switch that's either safe or dangerous for everyone. It's a decision that lives in the details of your specific body and history. A few conditions genuinely close the door, and I take those seriously. Many more are simply forks in the road, questions to answer, routes to choose, problems to solve first. If you've been carrying around a "no" that never got explained, or a "yes" you're not sure is safe, that's worth a real conversation. That's the kind of careful, individualized look we do every day at Magnolia Functional Wellness here in Southlake, and it's usually the difference between guessing and actually knowing.